Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Paynova in conjunction with raising of capital and change in listing
Mandate

Vinge advises Paynova in conjunction with raising of capital and change in listing

June 07, 2022 Capital Markets and Public M&A

Vinge has advised Paynova AB, under change of name to Sileon AB, in connection with a fully subscribed rights issue valued at approximately SEK 70 million.  

In connection with the issue, Paynova has also made public their intention to implement a change of listing from NGM Regulated to Nasdaq First North Growth Market.

Vinge’s team consisted of, among others, Anders Strid, Edin Agic (project manager), Adrian Filipovic and Amelia Rihs.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026